SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

This article was originally published here

The phase I/Ib study (SC103) will evaluate the safety and preliminary efficacy of SO-C101 in patients with selected advanced/metastatic solid tumours. The first patient was treated with SO-C101

The post SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply